News | January 28, 2014

ReCor Medical Advances Ultrasound-Based Renal Denervation System

ReCor Medical Paradise System Renal Denervation RDN Therapy Hypertension
January 28, 2014 — ReCor Medical advanced its Paradise System for renal denervation (RDN) for treatment resistant hypertension (HTN).
 
The company received CE marking for the latest generation of its ultrasound-based renal denervation system. Patients were treated with the system in December 2013 at the Universitats–Herzzentrum, Bad Krozingen, Germany by Prof. Thomas Zeller, M.D. and Elias Noory, M.D.
 
"The initial procedures with the Paradise System highlighted the generator's ability to automatically customize energy delivery based on the patient's artery size while maintaining a consistent level of cooling protection," Zeller and  Noory said.
 
Drs. Nicolas Van Mieghem and Joost Daemen, Erasmus Medical Center in Rotterdam, the Netherlands, used for the first time ReCor's Radiance catheter line, which is 5 French and rapid-exchange compatible to be introduced in the radial artery.
 
"Last Friday's procedures using the new Radiance catheter with access via the radial artery marks a significant new approach to making the RDN procedure quicker, safer and potentially more cost-effective for hospitals and patients," they said. “This system's radial artery access and 10 second ablation time should allow us to treat a patient in a minimally invasive way within 30 minutes, and then let that patient go home the same day."
 
The Paradise System uses radial ultrasound as its energy source with water-based convective cooling.
 
For more information: www.recormedical.com

Related Content

Videos | Cath Lab| January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab| January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab| November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab| November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab| November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab| November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Three-Year Quality of Life Improvements Similar for PCI and CABG in Left Main Disease
News | Cath Lab| October 30, 2017
October 30, 2017 — New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left m
Corindus Evaluates Incorporating HeartFlow Technology With CorPath GRX System
Technology | Cath Lab| October 26, 2017
Corindus Vascular Robotics Inc. announced that it will incorporate the HeartFlow FFRct (fractional flow reserve-...
Shockwave Medical Announces $35 Million in New Financing
News | Cath Lab| October 24, 2017
October 24, 2017 — Shockwave Medical reported $35 million in new financing, an extension of the company’s previously
Overlay Init